Lindus Health launches Medical Device CRO offering.
READ MORE
Announcing our Phase 2a clinical trial with PILA PHARMA to assess the tolerability, safety, and efficacy of XEN-D0501 in patients with type II diabetes and obesity.
We're pleased to announce the launch of our 7,500-participant trial with Aktiia!
PILA PHARMA INKS AGREEMENT WITH LINDUS HEALTH ABOUT NEXT CLINICAL TRIAL WITH SAFETY AND OBESITY READOUTS
Announcing our Phase 2a clinical trial with PILA PHARMA to assess the tolerability, safety, and efficacy of XEN-D0501 in patients with type II diabetes and obesity.
Lindus Health Launches Bespoke “All-in-One Medical Device CRO” Offering for Medical Device Clinical Trials
Introducing our newest CRO, site services, and eClinical technology offering to the medical device market.
Lindus Health and Tasso Establish Collaboration to Streamline Clinical Trials Through Remote Blood Collection
Lindus Health has adopted Tasso's remote blood collection technology to promote efficiency and patient-centricity in clinical trials.
Lindus Health Introduces “All-in-One Consumer Health CRO” Offering Tailored to Clinical Trials for Consumer Health Products
Introducing our "All-in-One Consumer Health CRO", designed with health and wellness sponsors in mind.
Prebiotic Fibre Supplement Significantly Reduces Risk of Developing Type 2 Diabetes, UK Study Finds
We're excited to share the positive results from our study with Myota in reducing risk of developing Type 2 diabetes.
Lindus Health and University of Oxford Publish Study Citing Key Strategies to Foster Diversity in Clinical Trial Participation
This collaboration with University of Oxford explores the perceptions of incentives and barriers to clinical trial participation among both researchers and various underrepresented groups.
